Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006079 · ClinicalTrials.gov registry record · Phase 2
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00006079: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00006079 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006079, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of cervical cancer. PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in preventing cervical cancer in patients who have cervical intraepithelial neoplasia.
Interventions
- OTHER Placebo
- DRUG Eflornithine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1998-06-19 |
| Est. Completion | 2004-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006079
The ClinicalTrials.gov registry entry for NCT00006079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00006079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006079 about?
NCT00006079 is a clinical study titled "Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of cervical cancer. PURPOSE: Randomized phase II trial to determine the effec...
What is the current status of trial NCT00006079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 1998-06-19. Estimated completion is 2004-04-27.
What interventions are being tested in trial NCT00006079?
The interventions under investigation include: Placebo (OTHER), Eflornithine (DRUG).
Who is sponsoring clinical trial NCT00006079?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.